Loading clinical trials...
Loading clinical trials...
An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention
Conditions
Interventions
Apixaban
vitamin K antagonist
+2 more
Locations
626
United States
Cardiovascular Associates of the Southeast, LLC
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Arizona Heart Rhythm Center
Phoenix, Arizona, United States
Local Institution
Phoenix, Arizona, United States
Scottsdale Osborn Medical Center
Scottsdale, Arizona, United States
Southern Arizona VA Health Care System
Tucson, Arizona, United States
Start Date
June 4, 2015
Primary Completion Date
November 10, 2018
Completion Date
November 10, 2018
Last Updated
June 11, 2020
NCT07429227
NCT07107971
NCT07268859
NCT07038265
NCT06765265
NCT06427694
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions